Chemomab Therapeutics (CMMB) Restructuring Costs (2020)

Chemomab Therapeutics (CMMB) posted Restructuring Costs of -$699000.0 for Q4 2020, down 984.81% on a QoQ basis from $79000.0 in Q3 2020.

Chemomab Therapeutics (CMMB) Restructuring Costs (2020) Analysis & Trends

Chemomab Therapeutics' Restructuring Costs history runs 1 years deep, the most recent figure standing at -$699000.0 for Q4 2020.

Quarterly Restructuring Costs changed N/A year-over-year to -$699000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $50000.0 (changed N/A YoY) and the FY2021 annual result came in at $216000.0, up 332.0% from the prior year.
Restructuring Costs was -$699000.0 for Q4 2020 at Chemomab Therapeutics, down from $79000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $670000.0 in Q1 2020 and bottomed at -$699000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Chemomab Therapeutics	729.63 Mn	719.26 Mn	-

Download Data